CA3063894A1 - Methods of use of soluble cd24 for neuroprotection and remyelination - Google Patents

Methods of use of soluble cd24 for neuroprotection and remyelination Download PDF

Info

Publication number
CA3063894A1
CA3063894A1 CA3063894A CA3063894A CA3063894A1 CA 3063894 A1 CA3063894 A1 CA 3063894A1 CA 3063894 A CA3063894 A CA 3063894A CA 3063894 A CA3063894 A CA 3063894A CA 3063894 A1 CA3063894 A1 CA 3063894A1
Authority
CA
Canada
Prior art keywords
protein
cd24fc
mins
human
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3063894A
Other languages
English (en)
French (fr)
Inventor
Yang Liu
Pan Zheng
Ning Li
Martin DEVENPORT
Original Assignee
Childrens National Medical Center Inc
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens National Medical Center Inc, Oncoimmune Inc filed Critical Childrens National Medical Center Inc
Publication of CA3063894A1 publication Critical patent/CA3063894A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3063894A 2017-05-15 2018-05-15 Methods of use of soluble cd24 for neuroprotection and remyelination Abandoned CA3063894A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506135P 2017-05-15 2017-05-15
US62/506,135 2017-05-15
PCT/US2018/032699 WO2018213266A1 (en) 2017-05-15 2018-05-15 Methods of use of soluble cd24 for neuroprotection and remyelination

Publications (1)

Publication Number Publication Date
CA3063894A1 true CA3063894A1 (en) 2018-11-22

Family

ID=64274583

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063894A Abandoned CA3063894A1 (en) 2017-05-15 2018-05-15 Methods of use of soluble cd24 for neuroprotection and remyelination

Country Status (8)

Country Link
US (2) US20200181235A1 (https=)
EP (1) EP3624838B1 (https=)
JP (1) JP2020519627A (https=)
KR (1) KR20200034957A (https=)
CN (1) CN110650749A (https=)
CA (1) CA3063894A1 (https=)
TW (1) TW201900671A (https=)
WO (1) WO2018213266A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
WO2021160170A1 (en) * 2020-02-10 2021-08-19 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US8808697B2 (en) * 2010-04-28 2014-08-19 Oncoimmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
US10689447B2 (en) * 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2887682A1 (en) * 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders

Also Published As

Publication number Publication date
TW201900671A (zh) 2019-01-01
EP3624838A4 (en) 2021-02-24
US20220098278A1 (en) 2022-03-31
JP2020519627A (ja) 2020-07-02
KR20200034957A (ko) 2020-04-01
CN110650749A (zh) 2020-01-03
WO2018213266A1 (en) 2018-11-22
US20200181235A1 (en) 2020-06-11
EP3624838A1 (en) 2020-03-25
EP3624838B1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
JP5738333B2 (ja) 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
US20220098278A1 (en) Methods of Use of Soluble CD24 for Neuroprotection and Remyelination
US20200399345A1 (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
JP5415071B2 (ja) Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用
US11026995B2 (en) Use of CD24 for lowering low-density lipoprotein cholesterol levels
KR20170074852A (ko) 대사 장애를 치료하기 위한 조성물 및 사용 방법
JP2012525847A (ja) Ｆｇｆ２１変異体およびその使用
WO2009125646A1 (ja) Ｔｄｐ－４３蓄積細胞モデル
JP2025116861A (ja) ペプチドおよび疾患の治療方法
US20150005229A1 (en) Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient
US20130011835A1 (en) Compositions and methods for treating inflammation
US20220104468A1 (en) Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
KR20230159847A (ko) 염증성 또는 활성화된 세포를 표적으로 하고 염증성 상태 및 통증을 치료 또는 개선하기 위한 조성물 및 방법
US20230108492A1 (en) Methods of use of soluble cd24 for treating viral pneumonia
US20210228680A1 (en) Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis
US7202211B2 (en) Methods of preventing or treating brain ischemia or brain injury
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법
EP1918299A1 (en) Modulators of cell adhesion molecules and use thereof
US20220000974A1 (en) Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
US7737250B2 (en) Peptides for treating axonal damage, inhibition of neurotransmitter release and pain transmission, and blocking calcium influx in neurons

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231116